Close menu

July 13th, 2022 | 14:27 CEST

MorphoSys facing a takeover? Exciting autumn ahead for BioNTech and XPhyto

  • Biotechnology
Photo credits:

Biotech investors could be in for an exciting autumn. After some sharp price corrections, positive things are happening again in the biotech sector. For one thing, the takeover carousel. It all started in June when Pfizer announced the acquisition of migraine specialist Biohaven for USD 11.6 billion, and GlaxoSmithKline plans to swallow Sierra Oncology for around USD 1.9 billion. Recent deals include the acquisitions of ViaCyte, La Jolla Pharmaceutical and Pliant Therapeutics. MorphoSys is also a possible takeover candidate. It could be a win-win for the German biotech company if the price is attractive. Xphyto could also see at least one investment, as a market-ready product has great potential.

time to read: 3 minutes | Author: Fabian Lorenz

Table of contents:

    XPhyto with the gold standard - PCR test in just 20 to 25 minutes

    For Big Pharma, XPhyto Therapeutics might be worth a look. The Canadians are focused on developing next-generation drug formulations, diagnostics and new active pharmaceutical ingredients. After a slide of around 85% this year, the stock is trading at EUR 0.42, where it seems to have found a bottom. The current source of hope at XPhyto is an innovative pain patch. It can be applied just before injections. The rotigotine patch is based on the TDS platform technology developed by XPhyto's German subsidiary Vektor Pharma. Together with a strong sales partner, a huge market could be developed. According to Kuick Research, the global market for transdermal skin patches is expected to grow to about USD 20 billion by 2028. That would correspond to a threefold increase over the USD 6.5 billion in industry sales in 2020 (source: Research and Markets). Given the potential, XPhyto's market capitalization of around CAD 40 million should not deter a major player.

    Overall, XPhyto is actively researching in the areas of transdermal and orally dissolvable drug formulations. Already ready for the market is the gold standard among PCR corona tests. The advantage: XPhyto's COVID-ID test delivers results after only 20 to 25 minutes. That is because prior RNA extraction is not required as part of sample preparation. XPhyto thus closes the gap between inaccurate antigen tests and conventional PCR solutions whose testing takes up to 24 hours. So far, the Company has not been able to report significant sales success in this area, but perhaps there will be a second chance in the fall. So not only are voices increasing worldwide warning of a new COVID-19 wave in the fall, but initial action is being taken: TUI-Cruises, for example, are reintroducing mandatory masks, and the US has ordered a vaccine from Novavax. A strong sales partner could also give XPhyto a helping hand in this area.

    BioNTech - Booster for the share in the fall?

    BioNTech could also benefit from a new Corona wave in the fall. The new German biotech star is currently working on a COVID-19 vaccine adapted to the Omicron variant, which is now in the regulatory review process. In recent weeks, the share has performed well. Within three weeks, it went up from EUR 116 to EUR 164. The share was thus also unimpressed by the lawsuit filed by German competitor CureVac. CureVac has filed a lawsuit with the Düsseldorf Regional Court for patent infringement. The lawsuit concerns the mRNA technology and thus BioNTech's Corona vaccine Comirnaty. From CureVac's point of view, BioNTech has infringed several patents, for example, in the production of mRNA molecules. CureVac is therefore demanding appropriate compensation for an infringement of intellectual property rights. BioNTech rejected the accusations. The stock exchange seems to see it similarly.

    MorphoSys: Possible takeover by Incyte a win-win situation?

    And so back to the takeover carousel. MorphoSys is now also on this. The reason is an analyst study by RBC. The report speculates about a takeover by Incyte. The US company had a turnover of almost USD 3 billion last year and is thus significantly larger than MorphoSys. RBC believes that valuations in the biotech sector are currently attractive, including MorphoSys. The two companies are already partners. In mid-June, MorphoSys, Incyte and US giant Pfizer announced a collaboration on a clinical trial to further develop the MorphoSys product, Monjuvi. The trial will investigate whether the immunotherapeutic combination of Pfizer's novel TTI-622 fusion protein and Monjuvi (in combination with lenalidomide) can be used in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT). Monjuvi, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), received FDA approval in 2020. An acquisition could make sense for both sides: Incyte would significantly increase its pipeline. MorphoSys has so far made no progress in commercializing its pipeline, and the share price is trading at a 5-year low of just under EUR 22. Most recently, JPMorgan had rated the MorphoSys share as "Neutral", with a price target of EUR 34.

    The biotech sector is gaining momentum. The possible acquisition of MorphoSys by Incyte could be a win-win situation for both sides if the price is right. The acquisition of XPhyto could also make sense for a pharmaceutical company with strong sales. BioNTech shares have performed well in recent weeks and could benefit further from a booster program for the autumn wave.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!


    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.